Is Vesugen actually better than Cartalax

Vesugen has one small human cohort behind it and Cartalax has none, which is the most useful fact in any vesugen vs cartalax comparison. Short answer: Vesugen has the stronger evidence, but both are low-grade Khavinson tripeptides, and they aim at different tissues, so the better one depends on what you are trying to do.

I get this question from clients who have already read about both and want someone to pick for them. I can pick on evidence, and I'll do that below, but the evidence gap between them is smaller than it looks, so the goal matters more than the ranking.

What each one is supposed to do

Vesugen is Lys-Glu-Asp (KED), a tripeptide (a chain of three amino acids) developed for vascular endothelium, the thin cell layer lining your blood vessels. Cartalax is Ala-Glu-Asp (AED), a tripeptide developed from cartilage tissue that targets fibroblasts, the cells that build and maintain connective tissue including skin, tendon and ligament.

Both belong to the Khavinson family of short peptides. The proposed mechanism is the same in each case: the peptide enters the nucleus, binds DNA, and shifts which genes the cell reads. That shared mechanism is a proposal, and it has not been confirmed in humans for either one.

Evidence quality

Vesugen has two papers. In a mouse model of Alzheimer's disease, daily injections restored the density of mature dendritic spines in the hippocampus to control levels. That paper later received a correction notice because two figures were duplicated, and the authors say the conclusions hold. The second paper is the one that matters for the comparison: a small human cohort of 32 older adults with several chronic conditions, where Vesugen was associated with slower biological aging markers and looked stronger than Pinealon, the other peptide tested. It was unblinded, it came from a single Russian site, and the peptides were tested separately.

Cartalax has cell-culture work and nothing else. Human skin fibroblasts exposed to AED increased SIRT-1 and SIRT-6 (longevity-linked enzymes that depend on NAD+) and made more type I collagen. An earlier rat skin cell study found it suppressed MMP-9, an enzyme that degrades collagen and rises with age. A kidney cell study found lower p16, p21 and p53, which are markers that push cells toward senescence (a stalled, non-dividing state).

The Cartalax lab results are internally consistent and some of them use human cells. They are also all from one research group, with no animal study and no human data to say whether any of it happens in a living person. Vesugen sits one rung higher on the evidence ladder, though that rung is a single unblinded cohort.

Dose and cost

For Vesugen, the mouse study used 400 mcg/kg injected daily, which does not convert cleanly to people. What people actually run is about 100 to 200 mcg per day subcutaneously for 10 to 20 consecutive days, repeated two or three times a year.

Cartalax has the messiest dosing in the whole family. The Khavinson-school protocol is 5 to 10 mcg per day for 10 days, once to three times a year. The community protocol is 2 mg per day for 10 to 20 days, three or four times a year, which is 200 to 400 times higher. No dose-finding study exists to say which range is correct. If you go with the community number, a 20 mg vial reconstituted with 2 mL of bacteriostatic water makes the 2 mg dose 20 units on a U-100 insulin syringe.

The cost difference follows from that. A year of Vesugen cycles at community doses uses about 2 to 12 mg of peptide, and a year of Cartalax at the community dose uses about 60 to 160 mg. Vesugen is the cheaper habit by a wide margin unless you adopt the low Khavinson-school Cartalax dose, which would close the gap.

Before you write any of this down, the obligatory: The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Side-effect load

Neither compound has documented serious adverse events, and both come with the caveat that no Western pharmacovigilance data exists. The usual reports for Vesugen are occasional injection-site reactions and a mild headache early in a cycle. For Cartalax they are injection-site redness and transient swelling.

The difference is the cancer question. Cartalax's proposed mechanism includes p53 suppression and more cell proliferation, and nobody has studied it in oncology patients, so active or past cancer is a hard stop for me. Vesugen has no equivalent flag in the literature, although its record is too thin to treat that as a clean bill of health.

The larger practical risk for both is the supply chain. Khavinson-family peptides are the most counterfeited category on the gray market, and the thin literature makes it easy for a seller to claim anything. A third-party certificate of analysis matters more here than almost anywhere, and I walk through how to read one in this guide to certificates of analysis.

Who each one suits

If your interest is vascular health or general aging markers and you want the option with some human signal, Vesugen is the more defensible starting point. It is cheaper to run, and its record at least includes people.

If your interest is skin quality or long-term connective tissue upkeep, Cartalax is the one aimed at that tissue, with the understanding that the rationale is inferred from fibroblast cultures. For an active joint or tendon injury, BPC-157 and TB-500 have a far stronger record than either of these, and Cartalax makes more sense as a maintenance add-on after the acute problem is handled. I also see people ask whether a pair of Khavinson peptides is necessary, and I covered a related case in Vilon vs Cartalax.

My own read is that Vesugen wins on evidence and cost, Cartalax wins on tissue fit for skin and connective tissue, and neither has earned a grade above D. Pick by the target tissue, buy from a vendor who publishes batch testing, and keep the cycles short.

Thanks for reading! In health, Rick Gold